GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (NAS:TBPH) » Definitions » Equity-to-Asset

TBPH (Theravance Biopharma) Equity-to-Asset : 0.52 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Theravance Biopharma's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $185.65 Mil. Theravance Biopharma's Total Assets for the quarter that ended in Sep. 2024 was $356.11 Mil. Therefore, Theravance Biopharma's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.52.

The historical rank and industry rank for Theravance Biopharma's Equity-to-Asset or its related term are showing as below:

TBPH' s Equity-to-Asset Range Over the Past 10 Years
Min: -1   Med: 0.41   Max: 0.89
Current: 0.52

During the past 12 years, the highest Equity to Asset Ratio of Theravance Biopharma was 0.89. The lowest was -1.00. And the median was 0.41.

TBPH's Equity-to-Asset is ranked worse than
63.96% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs TBPH: 0.52

Theravance Biopharma Equity-to-Asset Historical Data

The historical data trend for Theravance Biopharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Equity-to-Asset Chart

Theravance Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.55 -0.65 -0.90 0.73 0.56

Theravance Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.56 0.55 0.54 0.52

Competitive Comparison of Theravance Biopharma's Equity-to-Asset

For the Biotechnology subindustry, Theravance Biopharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Equity-to-Asset falls into.



Theravance Biopharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Theravance Biopharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=212.995/381.999
=0.56

Theravance Biopharma's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=185.654/356.105
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theravance Biopharma  (NAS:TBPH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Theravance Biopharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Theravance Biopharma Business Description

Traded in Other Exchanges
Address
Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Executives
Rhonda Farnum officer: SVP, Comm & Medical Affairs 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Eli Samaha 10 percent owner ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007
Richard A Graham officer: SVP, Development 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kelly James Connor director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Brett A. Grimaud officer: SVP, Gen Counsel and Secretary 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Aziz Sawaf officer: SVP & Chief Financial Officer 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Rick E Winningham director, officer: Chief Executive Officer 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Andrew A. Hindman officer: SVP, Chief Financial Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Weiss Asset Management Lp 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Wam Gp Llc 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Philip D Worboys officer: SVP, Translational Science 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Brett K Haumann officer: VP-Clinical Develop. 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402